C.Z. Zhou

413 total citations
41 papers, 313 citations indexed

About

C.Z. Zhou is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, C.Z. Zhou has authored 41 papers receiving a total of 313 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in C.Z. Zhou's work include Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (10 papers) and Cancer Immunotherapy and Biomarkers (7 papers). C.Z. Zhou is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (10 papers) and Cancer Immunotherapy and Biomarkers (7 papers). C.Z. Zhou collaborates with scholars based in China, United States and Japan. C.Z. Zhou's co-authors include Yanshai Wang, Zhiyong Wei, Liang-Jiu Jia, Xuefei Leng, Yang Yu, Yang Li, Rui Zhang, Songwen Zhou, Chen Su and Bo Chen and has published in prestigious journals such as Environmental Pollution, British Journal of Cancer and Annals of Oncology.

In The Last Decade

C.Z. Zhou

36 papers receiving 308 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C.Z. Zhou China 9 93 90 79 58 54 41 313
Yaokun Chen China 10 65 0.7× 118 1.3× 76 1.0× 80 1.4× 37 0.7× 16 481
Rui Wei China 13 42 0.5× 144 1.6× 90 1.1× 42 0.7× 51 0.9× 21 398
Baik‐Hwan Cho South Korea 10 64 0.7× 84 0.9× 69 0.9× 54 0.9× 30 0.6× 18 351
Anna Kron Germany 12 77 0.8× 54 0.6× 90 1.1× 57 1.0× 19 0.4× 43 403
Yali Bai China 9 154 1.7× 91 1.0× 90 1.1× 152 2.6× 28 0.5× 16 344
Е. L. Choynzonov Russia 13 73 0.8× 139 1.5× 113 1.4× 85 1.5× 45 0.8× 89 469
Haiyang Zhang China 9 23 0.2× 119 1.3× 40 0.5× 51 0.9× 26 0.5× 24 308
Guangbin Li China 12 45 0.5× 96 1.1× 53 0.7× 46 0.8× 41 0.8× 34 348
Baochun Wang China 11 83 0.9× 181 2.0× 60 0.8× 161 2.8× 65 1.2× 20 364

Countries citing papers authored by C.Z. Zhou

Since Specialization
Citations

This map shows the geographic impact of C.Z. Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.Z. Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.Z. Zhou more than expected).

Fields of papers citing papers by C.Z. Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.Z. Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.Z. Zhou. The network helps show where C.Z. Zhou may publish in the future.

Co-authorship network of co-authors of C.Z. Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of C.Z. Zhou. A scholar is included among the top collaborators of C.Z. Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.Z. Zhou. C.Z. Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhou, Fang, Jian Zhang, Fashuai Li, Luoyang Ding, & C.Z. Zhou. (2024). MA15.04 MRD Predicts Clinical Outcomes of Patients with Early-Stage EGFR-Mutant NSCLC: A Post-Hoc Biomarker Analyses of EVIDENCE. Journal of Thoracic Oncology. 19(10). S117–S117. 1 indexed citations
2.
Park, K., Edurne Arriola, M. Pérol, et al.. (2024). P1.12B.10 Dose Adjustments and Exposure-Response Associated with Selpercatinib in Patients with Advanced NSCLC. Journal of Thoracic Oncology. 19(10). S205–S205. 1 indexed citations
3.
4.
Zhou, C.Z., et al.. (2024). Effects of long-term exposure to sulfamethoxazole on the sediments in sewage pipe: Extracellular polymeric substance, microbial communities, and antibiotic resistance genes. Journal of environmental chemical engineering. 13(1). 115116–115116. 4 indexed citations
5.
Xie, Yuling, et al.. (2024). Analysis and calculation of scour critical velocity of suspended particles in a storm sewer. Water Environment Research. 96(9). e11135–e11135.
6.
Qing, Xian, C.Z. Zhou, Huimin Liao, et al.. (2024). Development and application of an efficient GC-HRMS method for the determination of PBDD/Fs in flue gas and fly ash samples. Microchemical Journal. 207. 112050–112050.
7.
8.
Jia, Liang-Jiu, Rui Zhang, C.Z. Zhou, et al.. (2023). In-situ three-dimensional X-ray investigation on micro ductile fracture mechanism of a high-Mn steel with delayed necking effect. Journal of Materials Research and Technology. 24. 1076–1087. 16 indexed citations
9.
10.
11.
Felip, Enriqueta, Eric Vallières, C.Z. Zhou, et al.. (2021). LBA9 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC. Annals of Oncology. 32. S1319–S1319. 8 indexed citations
12.
13.
Ren, Shengxiang, Jun Zhao, G. Chen, et al.. (2020). 1267P Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC. Annals of Oncology. 31. S819–S819. 2 indexed citations
14.
Loong, Herbert H., Kōichi Goto, Yasir Y. Elamin, et al.. (2020). 1413TiP LIBRETTO-431: Selpercatinib in treatment (Tx)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC). Annals of Oncology. 31. S893–S893. 2 indexed citations
15.
Zhang, Yisheng, et al.. (2019). P2.14-51 Dual ALK Fusion Partners as Poor Predictive Marker in First Line Crizotinib Treated ALK Rearranged Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S849–S850. 2 indexed citations
16.
Zhou, C.Z., Christian Caglevic, Jianying Zhou, et al.. (2017). KEYNOTE-033: Phase 3 study of pembrolizumab versus docetaxel in patients with previously treated non–small-cell lung cancer (NSCLC). Annals of Oncology. 28. x143–x143. 3 indexed citations
17.
Zhou, C.Z., Ying Cheng, Y. Chen, et al.. (2017). Osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced NSCLC: Updated Phase II study results including progression-free survival (PFS). Annals of Oncology. 28. v484–v484. 2 indexed citations
18.
Cheng, Ying, Yi‐Long Wu, Tongtong An, et al.. (2017). MA 11.03 Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405). Journal of Thoracic Oncology. 12(11). S1844–S1844. 2 indexed citations
19.
Yang, Yu‐Xiao, Jun Xia, Xun‐Li Wang, et al.. (2010). Ubiquitin D is correlated with colon cancer progression and predicts recurrence for stage II-III disease after curative surgery. British Journal of Cancer. 103(7). 961–969. 55 indexed citations
20.
Zhou, C.Z., et al.. (2010). Predictive Effects of ERCC1 and XRCC3 SNP on Efficacy of Platinum-based Chemotherapy in Advanced NSCLC Patients. Japanese Journal of Clinical Oncology. 40(10). 954–960. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yaokun Chen Breakdown of academic impact, for papers by Rui Wei Breakdown of academic impact, for papers by Baik‐Hwan Cho Breakdown of academic impact, for papers by Anna Kron Breakdown of academic impact, for papers by Yali Bai Breakdown of academic impact, for papers by Е. L. Choynzonov Breakdown of academic impact, for papers by Haiyang Zhang Breakdown of academic impact, for papers by Guangbin Li Breakdown of academic impact, for papers by Baochun Wang
Rankless by CCL
2026